Use of statin therapy to reduce cardiovascular risk in older patients.

Current Gerontology and Geriatrics Research
N K Wenger, S J Lewis

Abstract

Background. Cardiovascular disease is the principal cause of mortality in older individuals, and more than 80% of deaths due to coronary heart disease or stroke occur in patients over 65 years of age. Hyperlipidemia is one of the main modifiable risk factors for cardiovascular disease. Current guidelines recommend the use of statins to reduce low-density lipoprotein cholesterol to appropriate targets based on an individual's cardiovascular risk, and clearly state that older age should not be a barrier to treatment. Despite extensive evidence demonstrating clear benefit with statin therapy in older individuals, this population remains chronically undertreated. Scope. This paper provides an overview of the current evidence available regarding the efficacy and safety of statin therapy to reduce cardiovascular risk in older patients. We use hypothetical case studies to address some of the questions frequently posed by physicians responsible for the cardiovascular health of older patients. Conclusions. Various factors may account for the failure to provide appropriate treatment, including a lack of awareness of clinical benefits and perceived safety issues. However, if current guidelines are followed and older patients treated to ap...Continue Reading

References

Sep 1, 1993·The Annals of Pharmacotherapy·H Y PanD Whigan
Mar 1, 1996·Journal of Clinical Pharmacology·D M GibsonL R Whitfield
Mar 20, 1998·Journal of Clinical Pharmacology·R SternJ Besserer
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Aug 18, 2000·Anaesthesia·Z Zych
Sep 20, 2000·Mayo Clinic Proceedings·G C Kane, J J Lipsky
Mar 7, 2001·The American Journal of Cardiology·M W MassingR J Simpson
Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Dec 26, 2001·Clinical Pharmacology and Therapeutics·K SugimotoA Fujimura
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Joshua S BennerJerry Avorn
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Cynthia A JackeviciusJack V Tu
Oct 5, 2002·Journal of Clinical Pharmacology·Paul D MartinMike J Warwick
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Apr 30, 2005·Preventive Cardiology·Alawi A Alsheikh-Ali, Richard H Karas
Jul 7, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Joshua S BennerSetareh A Williams
May 10, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·K G M M AlbertiJ Shaw
Jul 25, 2006·The American Journal of Geriatric Pharmacotherapy·Judith H Hey-HadaviBarbara Lepetri
Aug 5, 2006·European Heart Journal·Kausik K RayUNKNOWN PROVE IT-TIMI 22 Investigators
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
May 1, 2007·Journal of the American College of Cardiology·Michael H Davidson, Jennifer G Robinson
May 2, 2007·Hypertension·Philip B Mellen, David C Goff
Jun 15, 2007·The Annals of Pharmacotherapy·Tone WestergrenEspen Molden
Jul 4, 2007·Annals of Internal Medicine·Nanette K WengerUNKNOWN Treating to New Targets Study Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Sep 8, 2011·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Alyson HaslamUNKNOWN Georgia Centenarian Study
Jul 5, 2012·Age·Petra G van PeetWouter de Ruijter
Dec 3, 2014·Revista Española De Cardiología·Magda HerasPablo Avanzas
Dec 31, 2010·Revista española de cardiología·Leopoldo Pérez de IslaMagda Heras
May 3, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Jimmy JoseIbrahim Al Busaidi
Aug 20, 2011·International Journal of Clinical Practice·N Verma, V M Figueredo
Mar 25, 2019·The Journal of Clinical Endocrinology and Metabolism·Derek LeRoithAlan J Sinclair

❮ Previous
Next ❯

Software Mentioned

PROVE
MIRACL
SAGE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Hypertension Reports
Joey P GrangerBabbette LaMarca
Cleveland Clinic Journal of Medicine
David S Goldstein
Journal of Thrombosis and Haemostasis : JTH
T SimonEStrogen and THromboEmbolism Risk (ESTHER) Study Group
Circulation. Cardiovascular Quality and Outcomes
Francisco Lopez-JimenezVirend K Somers
© 2021 Meta ULC. All rights reserved